Alcon Receives FDA Approval for OTC Pataday Once Daily Relief for Allergy Relief

Source: Alcon

Alcon announced that Pataday Once Daily Relief (olopatadine hydrochloride ophthalmic solution 0.2%) and Pataday Twice Daily Relief (olopatadine hydrochloride ophthalmic solution 0.1%) have been approved by the FDA for sale over-the-counter (OTC) in the United States. The Pataday brand features the No. 1 doctor-prescribed eye allergy itch relief ingredient, and includes the first once daily allergy itch relief drop to be available without a prescription, according to an Alcon news release. 

“At Alcon, we are focused on delivering new eye care products and solutions that meet the needs of patients and consumers, including those who suffer from allergies,” Sergio Duplan, Region President, North America at Alcon, said in the news release. “We are proud to launch prescription-strength Pataday as a convenient, more easily accessible, over-the-counter option to relieve the itchy eyes that almost 1-in-5 Americans experience due to ocular allergies.”

The rights to the Rx-to-OTC switch were secured by Alcon as part of its separation from Novartis in April 2019. Alcon will market both Patanol Solution (olopatadine 0.1%) and Pataday Solution (olopatadine 0.2%) under the Pataday brand name as Pataday Twice Daily Relief and Pataday Once Daily Relief, respectively.

“While eye allergies impact millions of Americans, only a small percentage of those use over-the-counter allergy eye drops likely due to a lack of awareness of effective options that treat the problem at the source,” Michael Cooper, OD, Solinsky Eye Care, Hartford, Connecticut, said in the news release. “For years, olopatadine has been my ‘go-to’ eye drop for patients struggling with itchy allergy eyes and I’m thrilled they will now be able to get the same relief over the counter whenever they need it. My hope is that more allergy sufferers will discover the benefits of Pataday and add it to their medicine cabinet this spring allergy season and beyond.”

Pataday Once Daily Relief and Pataday Twice Daily Relief are indicated for the temporary relief of itchy eyes due to pollen, ragweed, grass, animal hair and dander for ages 2 and older. Pataday Twice Daily Relief is also indicated for the temporary relief of red eyes. Since 2008, over 40 million prescriptions have been written for olopatadine, the active ingredient in Pataday.

U.S. commercial availability of Pataday Once Daily Relief and Pataday Twice Daily Relief will begin March 2 in time for the start of spring allergy season, and will be available in all major drug, food and mass market retailers, as well as through online retailers. The launch is supported by a multimillion-dollar media plan, including a national TV advertising campaign and strong online presence to reach eye allergy sufferers.



Related Content